Company News
- CTD Holdings Engages Torreya Capital as Strategic Advisor
Nov 13, 2018, 8:43 AM EST - CTD Announces Partnership with Synteract to support the Extension Protocol for its Phase I Clinical Trial in the United States
Nov 8, 2018, 3:07 PM EST - CTD Holdings Announces Filing of Patent Application for Use of Hydroxypropyl Beta Cyclodextrins in the Treatment of Alzheimer’s Disease
Oct 29, 2018, 6:49 PM EDT - CTD Holdings Posts Recording of its Webinar on US Clinical Trial
Oct 18, 2018, 4:31 PM EDT - CTD Holdings Announces Plans to Broaden its Expanded Access Program for Trappsol® Cyclo™
Oct 15, 2018, 8:00 AM EDT - CTD Holdings to Host Webinar on its Phase I Clinical Trial for Niemann-Pick Disease Type C
Oct 11, 2018, 12:57 PM EDT - CTD Holdings to Present at BioFlorida Conference with update on Clinical Program Using Cyclodextrins to treat diseases with Unmet Medical Needs
Oct 9, 2018, 12:03 PM EDT - CTD Holdings Establishes Second Clinical Trial Site for US Phase I Clinical Study of Trappsol® Cyclo™ for Treatment of Niemann-Pick Disease Type C
Oct 5, 2018, 8:00 AM EDT - CTD announces encouraging top-line data from two ongoing clinical trials of Trappsol® Cyclo™ administered intravenously in Niemann Pick Disease Type C (NPC)
Oct 3, 2018, 8:00 AM EDT - CTD Holdings to Present at UK Annual Conference for NPC Patients, Families, and Health Professionals
Sep 13, 2018, 10:56 AM EDT
